Cervical cancer awareness and screening in Botswana
AM Mingo, CA Panozzo, YT DiAngi, JS Smith… - International Journal of …, 2012 - ijgc.bmj.com
Objective Cervical cancer remains a leading cause of death in many developing countries
because limited screening by Papanicolaou (Pap) smear. We sought to better understand …
because limited screening by Papanicolaou (Pap) smear. We sought to better understand …
[HTML][HTML] A cross-sectional study of HPV vaccine acceptability in Gaborone, Botswana
YT DiAngi, CA Panozzo, D Ramogola-Masire… - PloS one, 2011 - journals.plos.org
Background Cervical cancer is the most common cancer among women in Botswana and
elsewhere in Sub-Saharan Africa. We sought to examine whether HPV vaccine is …
elsewhere in Sub-Saharan Africa. We sought to examine whether HPV vaccine is …
[HTML][HTML] Taming the EHR (Electronic Health Record)-there is hope
YT DiAngi, CA Longhurst, TH Payne - Journal of family medicine, 2016 - ncbi.nlm.nih.gov
With increasing diffusion of EHR technology over the last half decade, clinician burnout is
rising. As healthcare is a complex and highly regulated field, the rapid and mass adoption of …
rising. As healthcare is a complex and highly regulated field, the rapid and mass adoption of …
[HTML][HTML] Timing between Rituximab and 90Y-Ibritumomab Tiuxetan in Pts with Non-Hodgkin's Lymphoma Does Not Affect Clinical Outcomes.
IE Friedman, C Andreadis, YT Diangi, SD Nasta… - Blood, 2006 - Elsevier
BACKGROUND: Rituximab, a chimeric, monoclonal antibody that specifically targets CD20,
is widely used in the treatment of non-Hodgkin's lymphoma (NHL). 90 Y ibritumomab …
is widely used in the treatment of non-Hodgkin's lymphoma (NHL). 90 Y ibritumomab …